Shopping Cart

Your shopping cart is currently empty

Tauroursodeoxycholate

Name: Tauroursodeoxycholate
Brand: TargetMol
SKU: T2532
Price: 37 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Hot

Catalog No. T2532Cas No. 14605-22-2

Alias Ursodeoxycholyltaurine, UR 906, TUDCA, Tauroursodeoxycholic Acid, Taurolite

Tauroursodeoxycholate (UR 906), also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

Tauroursodeoxycholate

Copy Product Info

🥰Excellent

Hot

Purity: 99.93%

Catalog No. T2532Alias Ursodeoxycholyltaurine, UR 906, TUDCA, Tauroursodeoxycholic Acid, TauroliteCas No. 14605-22-2

Pack Size	Price	USA Warehouse	Global Warehouse
25 mg	$37	In Stock	In Stock
50 mg	$50	In Stock	In Stock
100 mg	$63	In Stock	In Stock
500 mg	$146	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$50	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.93%

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	Tauroursodeoxycholate (UR 906), also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
In vitro	METHODS: HeLa cells overexpressing the WDR45 mutation were treated with Tauroursodeoxycholate (200 µM) for 24 h, and the expression levels of target proteins were measured by Western Blot. RESULTS: Inhibition of ER stress with Tauroursodeoxycholate significantly reduced the phosphorylation of p38 and LAMP2A as well as the punctate formation of mCherry KFERQ in cells expressing mutant WDR45. [1] METHODS: Undifferentiated neural stem cells NSCs were treated with Tauroursodeoxycholate (100 µM) for 24 h and cell proliferation was detected by Flow cytometry via BrdU. RESULTS: BrdU incorporation increased significantly after incubation with Tauroursodeoxycholate, and Tauroursodeoxycholate regulated cell proliferation. Tauroursodeoxycholate regulates cell proliferation.[2]
In vivo	METHODS: To test the effect on diabetes, Tauroursodeoxycholate (300 mg/kg) was administered intraperitoneally to STZ-induced diabetic C57BL/6 mice once daily for 24 days. RESULTS: After 15 days of treatment, STZ+Tauroursodeoxycholate mice had a 43% reduction in blood glucose compared to the STZ group. This decrease may be due to an increase in insulinemia. [3]
Synonyms	Ursodeoxycholyltaurine, UR 906, TUDCA, Tauroursodeoxycholic Acid, Taurolite

Chemical Properties

Molecular Weight	499.7
Formula	C₂₆H₄₅NO₆S
Cas No.	14605-22-2
Smiles	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CCC2C3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)C3CC[C@]12C
Relative Density.	1.216 g/cm3 (Predicted)

Storage & Solubility Information

Storage

keep away from direct sunlight | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: 100 mg/mL (200.12 mM), Sonication is recommended.

DMSO: 6.25 mg/mL (12.51 mM), Sonication is recommended.

In Vivo Formulation

5% DMSO+95% Saline: 4.5 mg/mL (9.01 mM), Solution.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO/H2O

	1mg	5mg	10mg	50mg
1 mM	2.0012 mL	10.0060 mL	20.0120 mL	100.0600 mL
5 mM	0.4002 mL	2.0012 mL	4.0024 mL	20.0120 mL
10 mM	0.2001 mL	1.0006 mL	2.0012 mL	10.0060 mL

H2O

	1mg	5mg	10mg	50mg
20 mM	0.1001 mL	0.5003 mL	1.0006 mL	5.0030 mL
50 mM	0.0400 mL	0.2001 mL	0.4002 mL	2.0012 mL
100 mM	0.0200 mL	0.1001 mL	0.2001 mL	1.0006 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc